Cargando...
Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences
AIMS: To characterize gastrointestinal adverse events (AEs) with different glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs). METHODS: Two retrospective intention‐to‐treat analyses of 6‐month patient‐level data were conducted. Data from three studies comparing exenatide once weekly (n = 617) with...
Gardado en:
| Publicado en: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Blackwell Publishing Ltd
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5412849/ https://ncbi.nlm.nih.gov/pubmed/28058769 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12872 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|